PMID- 16608981
OWN - NLM
STAT- MEDLINE
DCOM- 20070720
LR  - 20200203
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 17 Suppl 2
DP  - 2006 Mar
TI  - Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
      in non-small cell lung cancer.
PG  - ii46-48
AB  - Despite recent developments in the diagnosis and conventional treatment of non 
      small cell lung cancer (NSCLC), the prognosis remains unsatisfactory, with 5-year 
      survival rates of approximately 15% for all stages. To date, chemotherapy 
      represents the standard treatment for advanced-non small lung cancer, but 
      efficacy of currently available cytotoxic drugs is modest. Median survival does 
      not exceed 8-10 months. New treatment strategies are needed and considerable hope 
      has been placed in therapies that specifically target the molecular mechanisms of 
      tumour growth. One molecular target of particular relevance to lung cancer 
      pathogenesis is the epidermal growth factor receptor (EGFR), a cell membrane 
      receptor tyrosine kinase. Several inhibitors of EGFR fuctinonal activation have 
      been developed. Amon these, erlotinib (Tarceva) and gefitinib (Iressa) are two 
      orally bioavailable, small molecule EGFR inhibitors of the tyrosine kinase 
      enzymatic activity which prevent EGFR autophosphorylation and activation. In 
      monotherapy, gefitinib and erlotinib have determinated a 10-20% response rate and 
      a 30-50% symptom improvement in previously treated, chemotherapy refractory, 
      advanced NSCLC patients. Furthermore, a randomized, placebo controlled, 
      multicenter phase III study has shown a two months improvement in median survival 
      with erlotinib in the second or third line treatment of metastatic NSCLC 
      patients. We will summarize the clinical evidence on the anticancer activity of 
      small molecule EGFR inhibitors.
FAU - Cascone, T
AU  - Cascone T
AD  - Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica 
      Clinica e Sperimentale F. Magrassi e A. Lanzara, Seconda Universita degli Studi 
      di Napoli, Napoli, Italy.
FAU - Morelli, M P
AU  - Morelli MP
FAU - Ciardiello, F
AU  - Ciardiello F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Medical Oncology
MH  - Prognosis
MH  - Protein Kinase Inhibitors/administration & dosage
RF  - 16
EDAT- 2006/04/13 09:00
MHDA- 2007/07/21 09:00
CRDT- 2006/04/13 09:00
PHST- 2006/04/13 09:00 [pubmed]
PHST- 2007/07/21 09:00 [medline]
PHST- 2006/04/13 09:00 [entrez]
AID - S0923-7534(19)38153-0 [pii]
AID - 10.1093/annonc/mdj921 [doi]
PST - ppublish
SO  - Ann Oncol. 2006 Mar;17 Suppl 2:ii46-48. doi: 10.1093/annonc/mdj921.